Skip to main content

Peer Review reports

From: Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China

Original Submission
25 Apr 2020 Submitted Original manuscript
13 Oct 2020 Author responded Author comments - Wei Hongtao
21 Jul 2020 Reviewed Reviewer Report
15 Sep 2020 Reviewed Reviewer Report - Ramon Luengo-Fernandez
Resubmission - Version 2
13 Oct 2020 Submitted Manuscript version 2
26 Dec 2020 Author responded Author comments - Wei Hongtao
14 Nov 2020 Reviewed Reviewer Report
17 Dec 2020 Reviewed Reviewer Report - Ramon Luengo-Fernandez
Resubmission - Version 3
26 Dec 2020 Submitted Manuscript version 3
5 Jan 2021 Author responded Author comments - Wei Hongtao
Resubmission - Version 4
5 Jan 2021 Submitted Manuscript version 4
10 Jan 2021 Author responded Author comments - Wei Hongtao
Resubmission - Version 5
10 Jan 2021 Submitted Manuscript version 5
Publishing
13 Jan 2021 Editorially accepted
28 Jan 2021 Article published 10.1186/s12913-021-06084-1

You can find further information about peer review here.

Back to article page